Search Results - "ŠÍMA, P."

Lessons from the COVID-19 pandemic by Lochman, I, Thon, V, Šíma, P

“…The numbers of diagnosed and reported cases of infection with the SARS-CoV-2 virus causing the disease COVID-19, which grew into a global pandemic, have…”
Get more information

Epigenetic Alterations in Bladder Cancer by Porten, Sima P.

“…Purpose of Review Epigenetics refers to processes that alter gene expression without altering primary DNA. Over that past decade, there is a growing focus on…”
Get full text

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin by Chu, Carissa E, Sjöström, Martin, Egusa, Emily A, Gibb, Ewan A, Badura, Michelle L, Zhu, Jun, Koshkin, Vadim S, Stohr, Bradley A, Meng, Maxwell V, Pruthi, Raj S, Friedlander, Terence W, Lotan, Yair, Black, Peter C, Porten, Sima P, Feng, Felix Y, Chou, Jonathan

“…Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting NECTIN4 (encoded by the gene) approved for treatment-refractory metastatic urothelial…”
Get full text

Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer by COOPERBERG, Matthew R, COWAN, Janet E, HILTON, Joan F, REESE, Adam C, ZAID, Harras B, PORTEN, Sima P, SHINOHARA, Katsuto, MENG, Maxwell V, GREENE, Kirsten L, CARROLL, Peter R

“…Active surveillance (AS) is an option for the initial management of early-stage prostate cancer. Current risk stratification schema identify patients with…”
Get full text

Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance by PORTEN, Sima P, WHITSON, Jared M, COWAN, Janet E, COOPERBERG, Matthew R, SHINOHARA, Katsuto, PEREZ, Nannette, GREENE, Kirsten L, MENG, Maxwell V, CARROLL, Peter R

“…Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason…”
Get full text

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials by Kates, Max, Matoso, Andres, Choi, Woonyoung, Baras, Alexander S, Daniels, Marcus J, Lombardo, Kara, Brant, Aaron, Mikkilineni, Nina, McConkey, David J, Kamat, Ashish M, Svatek, Robert S, Porten, Sima P, Meeks, Joshua J, Lerner, Seth P, Dinney, Colin P, Black, Peter C, McKiernan, James M, Anderson, Chris, Drake, Charles G, Bivalacqua, Trinity J

“…To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG). Patients…”
Get full text

Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer by Washington, 3rd, Samuel L, Neuhaus, John, Meng, Maxwell V, Porten, Sima P

“…Racial disparities in guideline-based, appropriate treatment (ApT) may be a significant driving force for differences in survival for people with nonmetastatic…”
Get full text

Promotion Disparities in Academic Urology by Breyer, Benjamin N., Butler, Christi, Fang, Raymond, Meeks, William, Porten, Sima P., North, Amanda C., Anger, Jennifer T.

“…To better understand promotion timelines across gender and race/ethnicity and how academic output impacts promotion in urology. We examined the 2017 census. An…”
Get full text

Sex-specific Augmentation of Treatment Responses in Bladder Cancer by Chang, Kevin, Porten, Sima P.

Get full text

Optimizing cystectomy outcomes by Porten, Sima P., Master, Viraj A.

“…Both data analytics and patient‐centered approaches will be required to optimize outcomes after cystectomy and make meaningful changes. Advances in technology…”
Get full text

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605 by Black, Peter C, Tangen, Catherine M, Singh, Parminder, McConkey, David J, Lucia, M Scott, Lowrance, William T, Koshkin, Vadim S, Stratton, Kelly L, Bivalacqua, Trinity J, Kassouf, Wassim, Porten, Sima P, Bangs, Rick, Plets, Melissa, Thompson, Jr, Ian M, Lerner, Seth P

“…Although radical cystectomy (RC) is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder…”
Get full text

Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers by Eisner, Brian H, Porten, Sima P, Bechis, Seth K, Stoller, Marshall L

“…The epidemiological relationship between nephrolithiasis and type 2 diabetes mellitus is well-known. Patients with diabetes mellitus are at increased risk for…”
Get more information

Women in Leadership in Urology: The Case for Increasing Diversity and Equity by Chyu, Jennifer, Peters, Chloe E., Nicholson, Tristan M., Dai, Jessica C., Taylor, Jennifer, Garg, Tullika, Smith, Angela B., Porten, Sima P., Greene, Kirsten, Browning, Nicole, Harris, Elaine, Sutherland, Suzette E., Psutka, Sarah P.

“…There is a persistent male gender predominance in urology, especially with respect to female representation in leadership. We review the current status of…”
Get full text

Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022? by Szymaniak, Julie, Porten, Sima P.

Get full text

Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort by Chappidi, Meera R., Welty, Christopher, Choi, Woonyoung, Meng, Maxwell V., Porten, Sima P.

“…To evaluate the Cancer of the Bladder Risk Assessment (COBRA) score in The Cancer Genome Atlas (TCGA) bladder cancer cohort. Second, to investigate the utility…”
Get full text

Evaluation of URO17® to improve non-invasive detection of bladder cancer by Porten, Sima P., Wang, Elizabeth Y., Vohra, Poonam, Carroll, Peter R., Jahanfard, Sholeh, Kim, Nam W.

“…•URO17 demonstrated an overall sensitivity of 90% and a specificity of 88%.•No controls demonstrated a positive URO17 result, and URO17 superseded urine…”
Get full text

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors by Lotan, Yair, Boorjian, Stephen A., Zhang, Jingbin, Bivalacqua, Trinity J., Porten, Sima P., Wheeler, Thomas, Lerner, Seth P., Hutchinson, Ryan, Francis, Franto, Davicioni, Elai, Svatek, Robert S., Chen, Chun-Liang, Black, Peter C., Gibb, Ewan A.

“…Upstaging of clinical T1-T2 urothelial carcinoma (UC) to non-organ-confined (NOC) pathological stage ≥T3 or N+ at radical cystectomy (RC) is common. Tools for…”
Get full text

Management of Leg Ulcers Using Combined PRP Therapy on a Nanofiber Carrier: Results of a Pilot Study by ŠÍMA, P., SCHŮREK, J., FOROSTYAK, S., DŽUPA, V., ARENBERGER, P.

Get full text

Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma by Wallace, Andrew, Porten, Sima P, Lo, Amy A, Oreper, Daniel, Lounsbury, Nicolas, Havnar, Charles, Pechuan-Jorge, Ximo, Zill, Oliver A, Meng, Maxwell V

“…Renal cell carcinoma (RCC) with venous tumor thrombus (VTT) arising from the primary tumor occurs in approximately 10% of cases and is thought to represent…”
Get full text

The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy by Welty, Christopher J., Sanford, Thomas H., Wright, Jonathan L., Carroll, Peter R., Cooperberg, Matthew R., Meng, Maxwell V., Porten, Sima P.

“…BACKGROUND Risk stratification of patients with urothelial carcinoma of the bladder (UCB) after cystectomy has important clinical and research implications…”
Get full text